New antibiotic could be safer for diabetic foot infections

NCT ID NCT04714411

Completed Disease control Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the antibiotic omadacycline in 42 hospitalized adults with diabetic foot infections, some with bone infection. The goal was to see if it causes fewer kidney problems and gut infections compared to standard antibiotics. Researchers compared results to a group of similar patients who received usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omadacycline (an antibiotic)
What this could lead to: If successful, this could show that omadacycline is a safer antibiotic option for diabetic foot infections, reducing the risk of kidney damage and gut infections.
What could go wrong: This is a small, early study with only 42 participants. Results may not apply to all patients, and the drug may still cause side effects or not work as well as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE OSTEOMYELITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteomyelitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC FOOT INFECTION

Contacts and locations

Locations

Methodist Charlton Medical Center

Dallas, Texas, 75237, United States
Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.